Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Soyeon | - |
dc.contributor.author | Lee, Yoo Jin | - |
dc.contributor.author | Choi, Yunsuk | - |
dc.contributor.author | Kim, Misung | - |
dc.contributor.author | Kim, Hyun-Jun | - |
dc.contributor.author | Kim, Ji Eun | - |
dc.contributor.author | Oh, Suk Joong | - |
dc.contributor.author | Chae, Seoung Wan | - |
dc.contributor.author | Cha, Hee Jeong | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.date.accessioned | 2023-07-05T02:37:06Z | - |
dc.date.available | 2023-07-05T02:37:06Z | - |
dc.date.created | 2022-10-06 | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 2383-7837 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186089 | - |
dc.description.abstract | Background: The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.Methods: We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.Results: A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).Conclusions: Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한병리학회 | - |
dc.title | Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Suk Joong | - |
dc.identifier.doi | 10.4132/jptm.2022.07.26 | - |
dc.identifier.scopusid | 2-s2.0-85139143928 | - |
dc.identifier.wosid | 000870477600005 | - |
dc.identifier.bibliographicCitation | Journal of Pathology and Translational Medicine, v.56, no.5, pp.281 - 288 | - |
dc.relation.isPartOf | Journal of Pathology and Translational Medicine | - |
dc.citation.title | Journal of Pathology and Translational Medicine | - |
dc.citation.volume | 56 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 281 | - |
dc.citation.endPage | 288 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002876400 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordPlus | THERAPEUTIC TARGETS | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | CDC2/CDK1 | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MYC | - |
dc.identifier.url | https://www.jpatholtm.org/journal/view.php?doi=10.4132/jptm.2022.07.26 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.